Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy

NCT00878722 is registered in ClinicalTrials.gov with Valerio Therapeutics as lead sponsor.

NCT NCT00878722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00878722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy
Lead sponsor
Valerio Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2007
Completion date
April 30, 2012
Enrollment
41 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia